Log In
Wednesday 26th June 2019

GSK to be hit hard due to Avandia

3rd February 2011

Drug manufacturer GlaxoSmithKline has set aside £2.2bn ($3.4bn) in the fourth quarter of 2010 to cover legal costs ahead of charges relating to its diabetes drug Avandia, and a federal investigation into the company’s sales and promotional practices for nine other products in the United States.

Avandia was banned in Europe last year while the US restricted its use because of a suspected link to heart disease. The charge is in addition to a £1.57bn charge GSK announced in July to cover various legal settlements, including claims over Avandia, as well as antidepressant Paxil.


Share this page


There are no comments for this article, be the first to comment!

Post your comment

Only registered users can comment. Fill in your e-mail address for quick registration.

Your email address:

Your comment will be checked by a Healthcare Today moderator before it is published on the site.

Mayden - Innovative cloud-based web development for the healthcare sector
© Mayden Foundation 2019